INFLUENCE OF APOE GENOTYPES ON BIOCHEMICAL INDICES OF IRON AND LIPID METABOLISM IN PATIENTS WITH THE ENDOMETRIUM NEOPLASTIC DISEASES AND HEAL THY WOMEN

Objective. APOE genotype association with the level of iron in plasma and the risk of endometrial neoplastic diseases has not been studied. The aim of the work was to analyze the genotypic associations of the apolipoprotein E (APOE) with iron and lipid levels in endometrial hyperplasia (EH)/endometrial cancer (EC) patients and healthy women.

Materials and methods. The biochemical blood levels of iron and cholesterol metabolism detected in women d with diagnosed endometrial hyperplasia (53), endometrial cancer (87) and healthy women (70) are determined on an automated analyzer «OLYMPUS AU – 400”. The genotyping was performed with a PCR-RFLP (polymerase chain reaction with restriction fragment length polymorphism) technique.

Results. A statistically significant decrease in the levels of serum iron, transferrin saturation, high-density lipoprotein on the one hand, and a statistically significant increase in body mass index, triglycerides, very low density lipoproteins, atherogenic index in patients with endometrial adenocarcinoma was observed. Statistically significant differences in the distribution of E3, E4, E2 allele frequencies between patients and healthy women (P = 0.048) was revealed. E3 allele frequency was reduced, and the E2 allele
was increased in patients with EC. It was shown that the serum iron level was significantly increased in EC patients and healthy carriers of the genotype E3/E2 (P= 0,0014 and 0,0363 respectively). There was significantly elevated triglyceride level in carriers of the minor genotypes E2/E4, E4/E4 among patients with EH (0,0389).

Conclusions. Genotype E3/E2 compared with other APOE genotypes under study is associated with elevated levels of iron and the risk of endometrial cancer. The association APOE 2/2, 2/4, 4/4 as well as 3/2 with endometrial neoplastic diseases requires further investigation. The data obtained can be the basis for the creation of a marker system for determining a high level susceptibility to malignant disease of the female reproductive system.

1. Kaprin A. D., Starinskij V. V., Petrova G. V. Zlokachestvennye novoobrazovanija v Rossii v 2012 godu (zabolevaemost’ i smertnost’). [Kniga]. – Moskva: FGBU «MNIOI im. P. A. Gercena» Minzdrava Rossii, 2014. – str. 250.

2. Ashrafjan L. A., Kiseljov A. I., Mujzhnek E. L. Patogeneticheskaja profilaktika raka reproduktivnyh organov. [Kniga]. – Moskva: Dimitrejd Grafik Grupp, 2009. – str. 176.

3. Kulakov V. I., Prilepskaja V. N. Prakticheskaja ginekologija: klinicheskie lekcii. [Kniga]. – Moskva: MEDpress-inform, 2008. – str. 752.

4. Baranov V. S. Geneticheskij pasport – osnova individual’noj i prediktivnoj mediciny. [Kniga]. – Sankt – Peterburg: N‑L, 2009. – str. 528.

5. Kucher A. N., Babushkina N. P., Bujkin S. V., Puzyrjov V. P. Plejotropnye jeffekty genov predraspolozhennosti k mnogofaktornym zabolevanijam. [Zhurnal]. – Moskva: [b. n.], 2013 g. – T. 2. – str. 13–23.

6. Mehan M. R., Nunez-Iglesias J., Dai C. et al. An integrative modular approach to systematically predict. [Journal]//BMC Bioinformatics. – 2010. – Vol. 11. – pp. 1–12.

7. Weisgraber K. H., Rall S. C., Mahley R. W. Human E apoprotein heterogeneity: cysteine-arginine interchanges in the aminoacid sequence of the apo-E isoforms [Journal]//Journal of Biological Chemistry. – 1981. – Vol. 256. – pp. 9077–9083.

8. Jofre-Monseny L., Minihane A. M., Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. [Journal]//Molecular Nutrition & Food Research. – 2008. – Vol. 52. – pp. 131–145.

9. Villeneuve S., Brisson D., Marchant N. L., Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. [Journal]//Frontiers in Aging Neuroscience. – 2014. – Vol. 6. – pp. 1–11.

10. Lindemann K., Vatten L. J., Ellstrøm-Engh M, Eskild A. Serum lipids and endometrial cancer risk: Results from the HUNT-II study. [Journal]//International Journal of Cancer. – 2009. – Vol. 124. – pp. 2938–2941.

11. Huang Xi. Does iron have a role in breast cancer? [Journal]//Lancet Oncology. – 2009. – Vol. 9. – pp. 803–808.

12. Kondrashova T. V., Neriishi K, Ban S, et al. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. [Journal]//Biochimica et Biophysica Acta. – 2006. – Vol. 1762. – pp. 59–65.

13. Hong C. C., Ambrosone C. B., Ahn J. et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO‑1), iron intake, and risk of postmenopausal breast cancer [Journal]//Cancer Epidemiol Biomarkers Prev. – 2007. – Vol. 16. – pp. 1784–1794.

14. Gannon P. O., Medelci S., Le Page C. et al. Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. [Journal]//The International Journal of Cancer. – 2011. – Vol. 128. – pp. 2326–2334.

15. Marques O., da Silva B. M., Porto G, Lopes C. Iron homeostasis in breast cancer. [Journal]//Cancer Letters. – 2014. – Vol. 347. – pp. 1–14.

16. Watson M. A., Gay L., Stebbings W. S. et al. Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis [Journal//Clinical Science. – 2003. – Vol. 104. – pp. 537–545.

17. Slattery M. L., Sweeney C., Murtaugh M. et al. Associations between apoE genotype and colon and rectal cancer [Journal]// Carcinogenesis. – 2005. – Vol. 26. – pp. 1422–1429.

18. Huvila J., Brandt A., Rojas C. R. et al. Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors. [Journal]//International Journal of Gynecological Cancer. – 2009. – Vol. 19. – pp. 1226–1231.

19. Breslow J. L., Zannis V. I., SanGiacomo T. R. et al. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. [Journal]//The Journal of Lipid Research. – 1982. – Vol. 23. – pp. 1224–1235.

20. Pham T., Kodvawala A., Hui D. Y. The Receptor Binding Domain of Apolipoprotein E Is Responsible for Its Antioxidant Activity [Journal]//Biochemistry. – 2005. – Vol. 44. – pp. 7577–7582.

21. Miyata M., Smith J. D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. [Journal]//Nature Genetics. – 1996. – Vol. 14. – pp. 55–61.

22. Suri S., Heise V., Trachtenberg A. J., Mackay C. E. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ɛ2. Neuroscience and Biobehavioral Reviews. [Journal]//Neuroscience and Biobehavioral Reviews. – 2013. – Vol. 37. – pp. 2878–2886.

23. Van der A D. L., Marx J. J., Grobbee D. E. et al. Non–Transferrin-Bound Iron and Risk of Coronary Heart Disease in Postmenopausal Women [Journal]//Circulation. – 2006. – Vol. 113. – pp. 1942–1949.

24. Xu H., Finkelstein D. I., Adlard P. A. Interactions of metals and Apolipoprotein E in Alzheimer’s disease [Journal]//Frontiers in Aging Neuroscience. – 2014. – Vol. 6. – pp. 1–7.

25. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. [Journal]//Clinical And Experimental Immunology. – 2012. – Vol. 167. – pp. 195–205.

26. Okoh V., Deoraj A., Roy D. Estrogen-induced reactive oxygen speciesmediated signaling contribute to breast cancer [Journal]// Biochimica et Biophysica Acta. – 2011. – Vol. 1815. – pp. 115–133.

27. Cairns R. A., Harris I. S., Mak T. W. Regulation of cancer cell metabolism. [Journal]//Nature Reviews Cancer. – 2011. – Vol. 11. – pp. 85–95.

28. Trompet S., Jukema J. W., Katan M. B., et al. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study [Journal]//The American Journal of Epidemiology. – 2009. – Vol. 170. – pp. 1415–1421.

29. Kulminski A. M., Culminskaya I., Arbeev K. G. et al. Trade-off in the effect of the APOE gene on the ages at onset of cardiocascular disease and cancer across ages, gender, and human generations. [Journal]//Rejuvenation Res. – 2013. – Vol. 16. – pp. 28–34.

30. Kulminski A. M., Arbeev K. G., Culminskaya I. et al. Age, gender, and cancer but not neurodegenerative and cardiovascular diseases strongly modulate systemic effect of the Apolipoprotein E4 allele on lifespan. [Journal]//PLOS Genet. – 2014. – Vol. 10. – pp. 1–12.

31. Teslovich T. M., Musunuru K., Smith A. V., et al. Biological, clinical and population relevance of 95 loci for blood lipids [Journal]// Nature. – 2010. – Vol. 466. – pp. 707–713.

32. Khan T. A., Shah T., Prieto D., et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. [Journal]// International Journal of Epidemiology. – 2013. – Vol. 42. – pp. 475–492.

33. Seth D. Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study [Journal]//International Journal of Molecular Epidemiology and Genetics. – 2012. – Vol. 3. – pp. 122–133.